Sun Of India Loses Eloxatin Patent Dispute With Sanofi In U.S. Court
This article was originally published in PharmAsia News
Executive Summary
India's Sun Pharmaceuticals lost a U.S. court patent battle with Sanofi of France over its drug Eloxatin (oxaliplatin) for late-stage colon cancer